Benfotiamine
Useful mainly for people with diabetic peripheral neuropathy or at risk for glucose-related tissue damage.
Quick decision guide
May help most
People with diabetic peripheral neuropathy or at risk for glucose-related tissue damage
Common dosing range
300–600 mg/day split into 2–3 doses
When to expect effects
4–12 weeks for neuropathy symptom changes
Watch out for
Not a substitute for glycemic control; works alongside, not instead of, diabetes management
What is it
Benfotiamine is a lipid-soluble derivative of vitamin B1 (thiamine) with significantly higher bioavailability and tissue penetration than water-soluble thiamine forms. It is widely used for diabetic complications and other applications requiring elevated tissue thiamine levels.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
diabetic peripheral neuropathy Limited Evidence | Moderate reduction in neuropathy symptom score over 3–6 weeks | Adults with type 2 diabetes and symptomatic peripheral neuropathy | 4–12 weeks |
diabetic nephropathy (kidney biomarkers) Limited Evidence | Small reductions in urinary advanced glycation end-products and markers of renal inflammation | Adults with early diabetic nephropathy and inadequate glycemic control | Weeks to months |
advanced glycation end-product (AGE) reduction Limited Evidence | Reduced plasma and tissue AGE markers in small studies | People with diabetes or high glucose burden and elevated circulating AGEs | Weeks |
diabetic peripheral neuropathy
- Effect
- Moderate reduction in neuropathy symptom score over 3–6 weeks
- Best fit
- Adults with type 2 diabetes and symptomatic peripheral neuropathy
- Time
- 4–12 weeks
diabetic nephropathy (kidney biomarkers)
- Effect
- Small reductions in urinary advanced glycation end-products and markers of renal inflammation
- Best fit
- Adults with early diabetic nephropathy and inadequate glycemic control
- Time
- Weeks to months
advanced glycation end-product (AGE) reduction
- Effect
- Reduced plasma and tissue AGE markers in small studies
- Best fit
- People with diabetes or high glucose burden and elevated circulating AGEs
- Time
- Weeks
Evidence for 3 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
diabetic peripheral neuropathy
Disease adjunctRCTs — primarily from German research groups — using 300–600 mg/day of benfotiamine show significant reductions in neuropathy symptom scores (burning, tingling, numbness) compared to placebo over 3–6 weeks. The mechanism involves transketolase activation, diverting glucose metabolites away from pathways that damage nerves. Evidence quality is moderate; most trials are small and short-term.
Bottom line: Reasonable adjunct for symptomatic diabetic peripheral neuropathy; does not replace glycemic control.
diabetic nephropathy (kidney biomarkers)
Biomarker supportSmall clinical studies report that benfotiamine reduces urinary excretion of methylglyoxal-derived advanced glycation end-products and markers of inflammation in diabetic kidney disease. These are biomarker outcomes; no long-term trials have established effects on GFR decline or clinical renal endpoints.
Bottom line: Biomarker-level evidence only; not proven to preserve kidney function clinically.
advanced glycation end-product (AGE) reduction
Biomarker supportBenfotiamine activates transketolase, which reroutes excess glucose-6-phosphate and fructose-6-phosphate away from pathways that generate reactive dicarbonyls (methylglyoxal) responsible for AGE formation. Small clinical trials in diabetic patients show reduction in plasma AGEs. These are biomarker-level findings; the pathway from AGE reduction to clinical outcomes like retinopathy or cardiovascular disease is mechanistically plausible but not confirmed in outcome trials.
Bottom line: Mechanistically sound biomarker effect; clinical significance not yet demonstrated in large trials.
How it works
How to take it
What to track
3 commercial forms
Compare the main delivery options and what they’re best suited for.
Benfotiamine (S-benzoylthiamine O-monophosphate)
Standard supplement form. Look for products specifying benfotiamine content.
Lipid-soluble derivative; substantially higher bioavailability than water-soluble thiamine.
Benfotiamine + B-complex combinations
Common in diabetic neuropathy formulas.
Combined with other B vitamins (B6, B12, folate) for broader neurological support.
Benfotiamine + alpha-lipoic acid
Often used in diabetic neuropathy formulations.
Pairs neuropathy-supportive compounds.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Who should avoid it
- People with severe thiamine deficiency presenting with Wernicke's encephalopathy (require IV thiamine, not oral benfotiamine)
- People with serious liver or kidney disease without clinician guidance
Pregnancy & breastfeeding
Specific benfotiamine safety data in pregnancy are limited; food-source thiamine is safe but medicinal doses should be discussed with a clinician.
Interactions
Loop diuretics increase thiamine excretion; benfotiamine may help offset depletion
Benfotiamine addresses glucose-related complications but does not lower blood glucose; no direct drug interaction, but combined metabolic monitoring is appropriate
Food sources
| Food | Amount | %DV |
|---|---|---|
| Benfotiamine is not naturally found in foods in significant amounts; obtain through supplementation. | N/A | — |
| Roasted garlic (contains related allithiamine compounds) | Various | — |
Benfotiamine is not naturally found in foods in significant amounts; obtain through supplementation.
- Amount
- N/A
- %DV
- —
Roasted garlic (contains related allithiamine compounds)
- Amount
- Various
- %DV
- —
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
How is benfotiamine different from regular thiamine?⌄
Benfotiamine is lipid-soluble and achieves blood and tissue thiamine levels approximately 5-fold higher than equivalent oral doses of water-soluble thiamine. This makes it more effective for conditions requiring elevated tissue thiamine, particularly diabetic complications.
Is benfotiamine effective for diabetic neuropathy?⌄
Yes. Multiple clinical trials, primarily German research, support 300 to 600 mg per day for reducing pain and improving nerve function in diabetic neuropathy. Effects develop over weeks to months.
Does benfotiamine lower blood sugar?⌄
No. Benfotiamine does not lower blood glucose directly. It works by reducing glucose-driven damage pathways in tissues, not by changing glucose levels. Continue diabetes management as prescribed.
How long should I take benfotiamine?⌄
For chronic conditions like diabetic neuropathy, benfotiamine is typically used long-term, with effects evaluated every 3 to 6 months. Long-term safety is acceptable based on available research.
Can I take benfotiamine with other B vitamins?⌄
Yes. Benfotiamine is often combined with B6, B12, and folate in formulations for nerve health. The combination is well tolerated.
References by claim
Track Benfotiamine with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.